search
Back to results

Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema (NEMO)

Primary Purpose

Retinitis Pigmentosa, Cystoid Macular Edema

Status
Completed
Phase
Phase 2
Locations
Italy
Study Type
Interventional
Intervention
rhNGF 180 µg/ml eye drops solution
vehicle eye drops
Sponsored by
Ospedale San Raffaele
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Retinitis Pigmentosa

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Typical and atypical forms of retinitis pigmentosa (RP)
  2. Measurable ERG with a significant decrease in the amplitude .
  3. Reduction of the visual field (assessed with Humphrey field analyzer- HFA 24-2) and values of mean deviation> -3 decibel (dB).
  4. RP associated with CME documented by OCT (macular thickness greater than 250 uM) present for at least three months and not in treatment for at least one month;
  5. Best corrected visual acuity (BCVA) between 20/100 (2/10 or 0.1 logMAR) and 20/25 (8/10 or 0.7 logMAR) and best corrected visual acuity for near not exceeding II character
  6. Absence Other ocular confounding diseases
  7. Participant must be medically able to undergo the testing and study procedures required in the flowsheet of exam procedures.

Exclusion Criteria:

  1. Presence of diabetes-related macular edema, or macular edema associated with other causes such as choroideal neovascularization or after the eye surgery.
  2. patients with diabetes mellitus.
  3. Patients who have performed eye surgery in the previous three months.
  4. Evidence of an active eye infection.
  5. previous uveitis or evidence of intraocular inflammation.
  6. History or evidence of glaucoma or elevated intraocular pressure (IOP) greater than or equal to 21 mm Hg at baseline.
  7. abnormalities of the anterior segment or media opacities that prevent the assessment of the posterior segment of te eye
  8. The treatment with corticosteroids (systemic, periocular or intravitreal) from at least 3 months.
  9. The use of any topical medication other than the study drug for the treatment of ocular pathologies.
  10. Presence or history of any systemic or ocular disease or condition that may significantly limit of visual acuity or visual field, hindering the effectiveness of treatment in the study or its evaluation, or could interfere with the interpretation of The study results, or may be judged by the investigator incompatible with the visit program or with the procedures in the study.
  11. Known hypersensitivity to study drug or drugs procedural.
  12. Participation in another clinical study during the same period of this study or within 90 days of the screening visit / baseline.
  13. History of drug use, illegal drugs or alcohol abuse or addiction.
  14. Women of childbearing potential are excluded from participation in the study if they meet one of the following conditions:

    • currently pregnant or,
    • have a positive urine pregnancy test at screening / baseline or,
    • They plan to become pregnant during the treatment period of the study or,
    • They are breast-feeding or,
    • They are not available to use highly effective measures of birth control, such as: the oral hormonal contraceptives and / or mechanical barrier methods - spermicide in conjunction with a barrier such as a condom or diaphragm or during the 'entire course of the study and 30 days after treatment periods provided.

Sites / Locations

  • Ospedale San Raffaele
  • Ospedale Sacco

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

study group

control group

Arm Description

rhNGF 180 µg/ml eye drops solution

vehicle eye drops solution

Outcomes

Primary Outcome Measures

macular thickness
assessed by ocular coherence tomography (OCT)

Secondary Outcome Measures

visual field
mean deviation
macular photoreceptors thickness
assessed by OCT
macular thickness
assessed by OCT
electroretinogram (ERG)
amplitudes
visual acuity
contrast sensitivity
quality of life
number of cystoid macular edema relapses
number of drop out for inefficacy of the study treatment
adverse events

Full Information

First Posted
October 12, 2015
Last Updated
September 2, 2017
Sponsor
Ospedale San Raffaele
Collaborators
Dompé Farmaceutici S.p.A
search

1. Study Identification

Unique Protocol Identification Number
NCT02609165
Brief Title
Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema
Acronym
NEMO
Official Title
Nerve Growth Factor Eye Drops as a Novel Treatment for Vision Loss in Patients With Retinitis Pigmentosa: From Preclinical to Clinical Phase II Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2017
Overall Recruitment Status
Completed
Study Start Date
May 2015 (undefined)
Primary Completion Date
February 2017 (Actual)
Study Completion Date
February 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ospedale San Raffaele
Collaborators
Dompé Farmaceutici S.p.A

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study aims at investigating the therapeutic potential of recombinant human Nerve Growth Factor ( rhNGF ) eye drops treatment in patients with Retinitis Pigmentosa (RP) associated with cystoid macular edema (CME) in a phase II, randomized, double-masked, controlled clinical trial.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Retinitis Pigmentosa, Cystoid Macular Edema

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
45 (Actual)

8. Arms, Groups, and Interventions

Arm Title
study group
Arm Type
Active Comparator
Arm Description
rhNGF 180 µg/ml eye drops solution
Arm Title
control group
Arm Type
Placebo Comparator
Arm Description
vehicle eye drops solution
Intervention Type
Drug
Intervention Name(s)
rhNGF 180 µg/ml eye drops solution
Other Intervention Name(s)
recombinant human Nerve Growth Factor
Intervention Description
eye drops
Intervention Type
Drug
Intervention Name(s)
vehicle eye drops
Other Intervention Name(s)
vehicle eye drop solution
Intervention Description
placebo
Primary Outcome Measure Information:
Title
macular thickness
Description
assessed by ocular coherence tomography (OCT)
Time Frame
28 days of treatment
Secondary Outcome Measure Information:
Title
visual field
Description
mean deviation
Time Frame
28 days of treatment, 1 month, 6 months and 12 months of follow-up
Title
macular photoreceptors thickness
Description
assessed by OCT
Time Frame
28 days of treatment, 1 month,3 months, 6 months and 12 months of follow-up
Title
macular thickness
Description
assessed by OCT
Time Frame
1 month,3 months, 6 months and 12 months of follow-up
Title
electroretinogram (ERG)
Description
amplitudes
Time Frame
28 days of treatment, 1 month, 6 months and 12 months of follow-up
Title
visual acuity
Time Frame
28 days of treatment,1 month,3 months, 6 months and 12 months of follow-up
Title
contrast sensitivity
Time Frame
28 days of treatment, 1 month,3 months, 6 months and 12 months of follow-up
Title
quality of life
Time Frame
28 days of treatment, 1 month,3 months, 6 months and 12 months of follow-up
Title
number of cystoid macular edema relapses
Time Frame
through study completion, up to 12 months of follow-up
Title
number of drop out for inefficacy of the study treatment
Time Frame
through study completion, up to 12 months of follow-up
Title
adverse events
Time Frame
through study completion, up to 12 months of follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Typical and atypical forms of retinitis pigmentosa (RP) Measurable ERG with a significant decrease in the amplitude . Reduction of the visual field (assessed with Humphrey field analyzer- HFA 24-2) and values of mean deviation> -3 decibel (dB). RP associated with CME documented by OCT (macular thickness greater than 250 uM) present for at least three months and not in treatment for at least one month; Best corrected visual acuity (BCVA) between 20/100 (2/10 or 0.1 logMAR) and 20/25 (8/10 or 0.7 logMAR) and best corrected visual acuity for near not exceeding II character Absence Other ocular confounding diseases Participant must be medically able to undergo the testing and study procedures required in the flowsheet of exam procedures. Exclusion Criteria: Presence of diabetes-related macular edema, or macular edema associated with other causes such as choroideal neovascularization or after the eye surgery. patients with diabetes mellitus. Patients who have performed eye surgery in the previous three months. Evidence of an active eye infection. previous uveitis or evidence of intraocular inflammation. History or evidence of glaucoma or elevated intraocular pressure (IOP) greater than or equal to 21 mm Hg at baseline. abnormalities of the anterior segment or media opacities that prevent the assessment of the posterior segment of te eye The treatment with corticosteroids (systemic, periocular or intravitreal) from at least 3 months. The use of any topical medication other than the study drug for the treatment of ocular pathologies. Presence or history of any systemic or ocular disease or condition that may significantly limit of visual acuity or visual field, hindering the effectiveness of treatment in the study or its evaluation, or could interfere with the interpretation of The study results, or may be judged by the investigator incompatible with the visit program or with the procedures in the study. Known hypersensitivity to study drug or drugs procedural. Participation in another clinical study during the same period of this study or within 90 days of the screening visit / baseline. History of drug use, illegal drugs or alcohol abuse or addiction. Women of childbearing potential are excluded from participation in the study if they meet one of the following conditions: currently pregnant or, have a positive urine pregnancy test at screening / baseline or, They plan to become pregnant during the treatment period of the study or, They are breast-feeding or, They are not available to use highly effective measures of birth control, such as: the oral hormonal contraceptives and / or mechanical barrier methods - spermicide in conjunction with a barrier such as a condom or diaphragm or during the 'entire course of the study and 30 days after treatment periods provided.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Paolo Rama, MD
Organizational Affiliation
Ospedale San Raffaele. Milan
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ospedale San Raffaele
City
Milan
ZIP/Postal Code
20132
Country
Italy
Facility Name
Ospedale Sacco
City
Milan
Country
Italy

12. IPD Sharing Statement

Learn more about this trial

Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema

We'll reach out to this number within 24 hrs